Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose-escalation and expansion study of TRI-611 in advanced ALK-positive non-small cell lung cancer
CTR20263841Phase 2Active
- Sponsor
- Novotech
- Start
- Oct 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TRI-611 in non-small cell lung cancer (NSCLC), sponsored by Novotech. Primary endpoints: Part 1 treatment-emergent adverse events and dose-limiting toxicities, Part 2 objective response rate and 1 more. Started Oct 2026; status: active.
02
Drugs
TRI-611
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263841.